Login / Signup

Letter in response to 'The efficacy and safety of complement C5a inhibitors for patients with severe COVID-19: a systematic review and meta-analysis' by Tsai et al.

Endry H T LimAlexander P J VlaarSanne de BruinMatthijs C BrouwerDiederik van de Beek
Published in: Expert review of anti-infective therapy (2023)
Keyphrases
  • coronavirus disease
  • sars cov
  • early onset
  • respiratory syndrome coronavirus
  • drug induced